Clinuvel Pharmaceuticals (ASX:CUV) refocused resources to prioritize its three key areas of clinical development: vitiligo, adrenocorticotropic hormone, and porphyrias, according to a Monday filing with the Australian bourse.
The decision is based on the need to optimize the company's internal resources, the likelihood of reimbursement for treatments, and new clinical guidelines related to central nervous system disorders.
The company also temporarily suspended its clinical programs in stroke, Parkinson's disease, and xeroderma pigmentosum, the filing said.
Clinuvel Pharmaceuticals will also continue to develop its non-pharmaceutical photocosmetic products.
The company's shares fell almost 1% in recent Monday trade.
Price (AUD): $13.20, Change: $-0.08, Percent Change: -0.60%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。